Important note

This AI stock analysis for Amgen is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Amgen - AI Stock Analysis

Analysis generated November 6, 2024

Amgen Inc., headquartered in Thousand Oaks, California, is one of the world's leading biotechnology companies. It focuses on human therapeutics and has a robust portfolio of products aimed at addressing severe illnesses. The company's approach includes leveraging advances in cellular and molecular biology to generate unique, innovative therapies.

Fundamental Analysis

The latest revenue figures for Amgen stood at $8.5 billion for the last quarter. This represents a slight decrease of 0.21% from the previous quarter, signaling potential concerns. Nonetheless, in comparison to the same quarter last year, revenue increased by 34.41%, indicating strong year-over-year growth.

Net income for the last quarter was $2.83 billion, an impressive increase of 279.36% compared to the previous quarter. Year-over-year growth in net income was also strong, having increased by 63.58% from the same quarter last year. This robust growth in net income is a positive indicator.

The company's EBITDA was $5.08 billion in the last quarter, an increase of 81.19% from the previous quarter. Year-over-year, the EBITDA grew by 49.37%, reflecting a strong operational performance.

The current Price to Earnings (P/E) ratio stands at 40.79. While high P/E ratios can often signal company growth potential, it can also indicate overvaluation, possibly leading to a bearish outlook.

Technical Analysis

Today’s stock price for Amgen is $319.29. Although there is a short-term decrease of 0.12% compared to a month ago, which might raise concerns, the long-term trend is positive with an increase of 21.32% compared to a year ago, bolstering a bullish outlook.

The Simple Moving Average (SMA10) is currently at 318.20, which is slightly above the previous SMA10 of 317.97. This uptick signals potential upward movement in the price.

The Relative Strength Index (RSI) stands at 39.5, suggesting a neutral sentiment. A neutral RSI indicates that the stock is neither overbought nor oversold.

Alternative Data Analysis

Amgen is actively hiring, with 662 open positions, an increase of 17% over the past few months. This surge suggests that the company is in growth mode, often a healthy sign for future performance. However, the business outlook among employees remains neutral.

The company's online presence is strengthening. Amgen’s website has an estimated 810,000 visitors, up by 53% recently, reflecting heightened customer interest. On social media, Amgen's Instagram followers have grown by 5% to 26,000, indicative of increased interest, whereas their Twitter followers stagnate at 120,000 with no change, showing a mixed signal in customer engagement.

Moreover, AltIndex’s AI score, which uses multifaceted analytical methods, rates Amgen with a score of 61. This score interprets data signals and assigns a "buy" recommendation.

Conclusion

Amgen presents a mixed but predominantly positive financial and growth trajectory. The robust year-over-year increases in revenue (34.41%), net income (63.58%), and EBITDA (49.37%) establish strong financial health, despite minor quarter-over-quarter fluctuations. While the elevated P/E ratio of 40.79 raises some concern about overvaluation, the company's growth prospects seem intact.

From a technical perspective, the stock price shows a long-term uptrend complemented by a neutral RSI of 39.5 and a marginally increasing SMA10. In terms of alternative data, increased job postings and website traffic suggest continued growth, even as the business outlook from employees holds at neutral.

Given these comprehensive insights, the overall recommendation leans towards a "buy," underpinned by strong year-over-year financial performance, promising long-term stock trends, and favorable alternative data metrics.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.